RT Journal Article
T1 CD4 T-Cell Subsets and the Pathophysiology of Inflammatory Bowel Disease
A1 Gómez Bris, Raquel
A1 Saez, Ángela
A1 Herrero Fernández, Beatriz
A1 Rius, Cristina
A1 Sánchez Martínez, Héctor
A1 González Granado, José María
AB Inflammatory bowel disease (IBD) is an umbrella term for the chronic immune-mediated idiopathic inflammation of the gastrointestinal tract, manifesting as Crohn's disease (CD) or ulcerative colitis (UC). IBD is characterized by exacerbated innate and adaptive immunity in the gut in association with microbiota dysbiosis and the disruption of the intestinal barrier, resulting in increased bacterial exposure. In response to signals from microorganisms and damaged tissue, innate immune cells produce inflammatory cytokines and factors that stimulate T and B cells of the adaptive immune system, and a prominent characteristic of IBD patients is the accumulation of inflammatory T-cells and their proinflammatory-associated cytokines in intestinal tissue. Upon antigen recognition and activation, CD4 T-cells differentiate towards a range of distinct phenotypes: T helper(h)1, Th2, Th9, Th17, Th22, T follicular helper (Tfh), and several types of T-regulatory cells (Treg). T-cells are generated according to and adapt to microenvironmental conditions and participate in a complex network of interactions among other immune cells that modulate the further progression of IBD. This review examines the role of the CD4 T-cells most relevant to IBD, highlighting how these cells adapt to the environment and interact with other cell populations to promote or inhibit the development of IBD.
PB MDPI
SN 1422-0067
YR 2023
FD 2023-01-31
LK https://hdl.handle.net/20.500.14352/93569
UL https://hdl.handle.net/20.500.14352/93569
LA eng
NO Gomez-Bris R, Saez A, Herrero-Fernandez B, Rius C, Sanchez-Martinez H, Gonzalez-Granado JM. CD4 T-Cell Subsets and the Pathophysiology of Inflammatory Bowel Disease. Int J Mol Sci. 2023 Jan 31;24(3):2696. doi: 10.3390/ijms24032696. PMID: 36769019; PMCID: PMC9916759.
NO Instituto de Salud Carlos III
NO European Regional Development Fund
DS Docta Complutense
RD 7 oct 2024